• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

γδ T 细胞受体来源于乳腺癌浸润 T 淋巴细胞,介导抗肿瘤反应。

γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.

机构信息

Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Institute for Surgical Pathology, University Medical Center, University of Freiburg, Freiburg, Germany.

出版信息

Cancer Immunol Res. 2020 Apr;8(4):530-543. doi: 10.1158/2326-6066.CIR-19-0513. Epub 2020 Feb 4.

DOI:10.1158/2326-6066.CIR-19-0513
PMID:32019779
Abstract

γδ T cells in human solid tumors remain poorly defined. Here, we describe molecular and functional analyses of T-cell receptors (TCR) from tumor-infiltrating γδ T lymphocytes (γδ TIL) that were in direct contact with tumor cells in breast cancer lesions from archival material. We observed that the majority of γδ TILs harbored a proinflammatory phenotype and only a minority associated with the expression of IL17. We characterized TCRγ or TCRδ chains of γδ TILs and observed a higher proportion of Vδ2 T cells compared with other tumor types. By reconstructing matched Vδ2 TCRγ and TCRδ pairs derived from single-cell sequencing, our data suggest that γδ TILs could be active against breast cancer and other tumor types. The reactivity pattern against tumor cells depended on both the TCRγ and TCRδ chains and was independent of additional costimulation through other innate immune receptors. We conclude that γδ TILs can mediate tumor reactivity through their individual γδ TCR pairs and that engineered T cells expressing TCRγ and δ chains derived from γδ TILs display potent antitumor reactivity against different cancer cell types and, thus, may be a valuable tool for engineering immune cells for adoptive cell therapies.

摘要

γδ T 细胞在人体实体肿瘤中的特征仍不明确。在这里,我们描述了来自乳腺癌病变中与肿瘤细胞直接接触的肿瘤浸润 γδ T 淋巴细胞 (γδ TIL) 的 T 细胞受体 (TCR) 的分子和功能分析。我们观察到,大多数 γδ TIL 具有促炎表型,只有少数与 IL17 的表达相关。我们对 γδ TIL 的 TCRγ 或 TCRδ 链进行了表征,并观察到与其他肿瘤类型相比,Vδ2 T 细胞的比例更高。通过对来自单细胞测序的匹配 Vδ2 TCRγ 和 TCRδ 对进行重建,我们的数据表明 γδ TIL 可能对乳腺癌和其他肿瘤类型具有活性。针对肿瘤细胞的反应模式取决于 TCRγ 和 TCRδ 链,并且独立于通过其他先天免疫受体进行的额外共刺激。我们得出结论,γδ TIL 可以通过其各自的 γδ TCR 对介导肿瘤反应,并且表达源自 γδ TIL 的 TCRγ 和 δ 链的工程化 T 细胞对不同的癌细胞类型具有强大的抗肿瘤反应性,因此可能是用于过继细胞疗法的免疫细胞工程的有价值的工具。

相似文献

1
γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.γδ T 细胞受体来源于乳腺癌浸润 T 淋巴细胞,介导抗肿瘤反应。
Cancer Immunol Res. 2020 Apr;8(4):530-543. doi: 10.1158/2326-6066.CIR-19-0513. Epub 2020 Feb 4.
2
Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.携带γδ(+)T细胞受体的肿瘤浸润淋巴细胞对层粘连蛋白受体阳性的人肺癌的杀伤作用。
J Natl Cancer Inst. 1996 Apr 3;88(7):436-41. doi: 10.1093/jnci/88.7.436.
3
Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.炎症性 CCR2/CCL2 趋化因子通路通过募集 1 型细胞毒性 γδ T 淋巴细胞到肿瘤床中的保护作用。
J Immunol. 2013 Jun 15;190(12):6673-80. doi: 10.4049/jimmunol.1300434. Epub 2013 May 17.
4
Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.人类肠道Vδ1 +淋巴细胞可识别上皮来源的肿瘤细胞。
J Exp Med. 1996 Apr 1;183(4):1681-96. doi: 10.1084/jem.183.4.1681.
5
Renal Cell Carcinoma-Infiltrating CD3 Vγ9Vδ1 T Cells Represent Potentially Novel Anti-Tumor Immune Players.肾细胞癌浸润的 CD3 Vγ9Vδ1 T 细胞代表潜在的新型抗肿瘤免疫效应细胞。
Curr Issues Mol Biol. 2021 May 27;43(1):226-239. doi: 10.3390/cimb43010019.
6
Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.双特异性抗体增强了针对自体 HER-2 表达的高级别卵巢肿瘤浸润 T 细胞的细胞毒性。
J Leukoc Biol. 2020 Jun;107(6):1081-1095. doi: 10.1002/JLB.5MA1119-265R. Epub 2019 Dec 13.
7
γδ T cells in human colon adenocarcinomas comprise mainly Vδ1, Vδ2, and Vδ3 cells with distinct phenotype and function.人结肠腺癌中的 γδ T 细胞主要由具有不同表型和功能的 Vδ1、Vδ2 和 Vδ3 细胞组成。
Cancer Immunol Immunother. 2024 Jul 2;73(9):174. doi: 10.1007/s00262-024-03758-7.
8
γδ T cells in cancer immunotherapy.癌症免疫疗法中的γδ T细胞。
Oncotarget. 2017 Jan 31;8(5):8900-8909. doi: 10.18632/oncotarget.13051.
9
Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.外周血中固定化抗 TCRγδ抗体扩增的人γδ T 细胞过继免疫治疗肺癌。
Cancer Biol Ther. 2009 Aug;8(16):1540-9. doi: 10.4161/cbt.8.16.8950. Epub 2009 Aug 8.
10
The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.人类 γδ T 细胞的双重作用:抗肿瘤或促进肿瘤。
Front Immunol. 2021 Feb 16;11:619954. doi: 10.3389/fimmu.2020.619954. eCollection 2020.

引用本文的文献

1
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HRHER2 breast cancer via CX3CR1 macrophages.分泌白细胞介素-17A的γδ T细胞通过CX3CR1巨噬细胞促进HRHER2乳腺癌对细胞周期蛋白依赖性激酶4/细胞周期蛋白依赖性激酶6抑制剂的抗性。
Nat Cancer. 2025 Jul 7. doi: 10.1038/s43018-025-01007-z.
2
Remodelling hypoxic TNBC microenvironment restores antitumor efficacy of Vγ9Vδ2 T cell therapy.重塑缺氧三阴性乳腺癌微环境可恢复Vγ9Vδ2 T细胞疗法的抗肿瘤疗效。
Br J Cancer. 2025 May 28. doi: 10.1038/s41416-025-03045-x.
3
Application of mass cytometry in the immune microenvironment of breast cancer.
质谱流式细胞术在乳腺癌免疫微环境中的应用。
Med Oncol. 2025 May 19;42(6):215. doi: 10.1007/s12032-025-02770-w.
4
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells.乳腺癌与肿瘤微环境:免疫细胞的关键作用
Curr Oncol. 2025 Feb 28;32(3):143. doi: 10.3390/curroncol32030143.
5
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.慢性粒细胞白血病(CML)的经验有助于阐明天然T细胞作为效应细胞在控制残留癌细胞中的作用以及作为癌症治疗潜在靶点的作用。
Front Immunol. 2024 Nov 15;15:1473139. doi: 10.3389/fimmu.2024.1473139. eCollection 2024.
6
The therapeutic role of γδT cells in TNBC.γδT 细胞在三阴性乳腺癌中的治疗作用。
Front Immunol. 2024 Jun 12;15:1420107. doi: 10.3389/fimmu.2024.1420107. eCollection 2024.
7
Update on current and new potential immunotherapies in breast cancer, from bench to bedside.乳腺癌当前及新的潜在免疫疗法进展:从实验室到临床应用
Front Immunol. 2024 Feb 15;15:1287824. doi: 10.3389/fimmu.2024.1287824. eCollection 2024.
8
Gamma/delta T cells as cellular vehicles for anti-tumor immunity.γ/δ T细胞作为抗肿瘤免疫的细胞载体。
Front Immunol. 2024 Jan 11;14:1282758. doi: 10.3389/fimmu.2023.1282758. eCollection 2023.
9
The capability of heterogeneous γδ T cells in cancer treatment.异质性 γδ T 细胞在癌症治疗中的作用。
Front Immunol. 2023 Nov 24;14:1285801. doi: 10.3389/fimmu.2023.1285801. eCollection 2023.
10
Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies.改善用于治疗实体恶性肿瘤的工程化γδT细胞受体疗法的策略。
Front Immunol. 2023 Jun 27;14:1159337. doi: 10.3389/fimmu.2023.1159337. eCollection 2023.